In VivoLarge pharmaceutical companies are eager to talk about their digital transformation and their whole-hearted adoption of computational biology and artificial intelligence (AI). In the same vein, many a
In VivoAs we discussed in Part 1 of this article, pharma is deriving value from applications of digital pathology across the spectrum of drug discovery and development. However, despite its promise, provider